- Home
- WRAP vs CMRX Comparison
WRAP vs CMRX Comparison
Compare WRAP & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- CMRX
- Stock Information
- Founded
- WRAP 2016
- CMRX 2000
- Country
- WRAP United States
- CMRX United States
- Employees
- WRAP N/A
- CMRX N/A
- Industry
- WRAP Ordnance And Accessories
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- CMRX Health Care
- Exchange
- WRAP Nasdaq
- CMRX Nasdaq
- Market Cap
- WRAP 68.8M
- CMRX 77.0M
- IPO Year
- WRAP N/A
- CMRX 2013
- Fundamental
- Price
- WRAP $1.70
- CMRX $0.93
- Analyst Decision
- WRAP
- CMRX Strong Buy
- Analyst Count
- WRAP 0
- CMRX 1
- Target Price
- WRAP N/A
- CMRX $11.00
- AVG Volume (30 Days)
- WRAP 191.1K
- CMRX 119.4K
- Earning Date
- WRAP 10-15-2024
- CMRX 11-08-2024
- Dividend Yield
- WRAP N/A
- CMRX N/A
- EPS Growth
- WRAP N/A
- CMRX N/A
- EPS
- WRAP N/A
- CMRX N/A
- Revenue
- WRAP $7,269,000.00
- CMRX $144,000.00
- Revenue This Year
- WRAP N/A
- CMRX $3,040.12
- Revenue Next Year
- WRAP N/A
- CMRX N/A
- P/E Ratio
- WRAP N/A
- CMRX N/A
- Revenue Growth
- WRAP 0.99
- CMRX N/A
- 52 Week Low
- WRAP $1.21
- CMRX $0.75
- 52 Week High
- WRAP $7.01
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- WRAP 56.79
- CMRX 60.78
- Support Level
- WRAP $1.71
- CMRX $0.80
- Resistance Level
- WRAP $1.93
- CMRX $0.98
- Average True Range (ATR)
- WRAP 0.16
- CMRX 0.05
- MACD
- WRAP 0.01
- CMRX 0.01
- Stochastic Oscillator
- WRAP 61.70
- CMRX 83.33
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc offers public safety technologies and services. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.